The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: A randomized controlled phase I/II study

Tuberculosis

Volumn 93, Issue 2, 2013, Pages 179-188

  Spertini, François ^a   Audran, Régine ^a   Lurati, Floriana ^a   Ofori Anyinam, Opokua ^b   Zysset, Frédéric ^a   Vandepapelière, Pierre ^b   Moris, Philippe ^b   Demoitié, Marie Ange ^b   Mettens, Pascal ^b   Vinals, Carlota ^b   Vastiau, Ilse ^b   Jongert, Erik ^b   Cohen, Joe ^b   Ballou, W Ripley ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b GSK   (Belgium)

Author keywords

Mtb72F AS02 vaccine; PPD positive; Tuberculosis

Indexed keywords

BCG VACCINE; C REACTIVE PROTEIN; CYTOKINE; IMMUNOGLOBULIN E;

ABSENCE OF SIDE EFFECTS; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; MALE; MYCOBACTERIUM TUBERCULOSIS; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; TH2 CELL; TREATMENT RESPONSE; TUBERCULOSIS;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; BCG VACCINE; CD4-POSITIVE T-LYMPHOCYTES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; INTERFERON-GAMMA; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; T-LYMPHOCYTE SUBSETS; TUBERCULIN; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINATION; YOUNG ADULT;

EID: 84875231727     PISSN: 14729792     EISSN: 1873281X     Source Type: Journal    
DOI: 10.1016/j.tube.2012.10.011     Document Type: Article

References (38)

1. World Health Organization Global tuberculosis control: WHO report 2011 2011 WHO Geneva, Switzerland Report no.: WHO/HTM/TB/2011.16
2. N.R. Gandhi, N.S. Shah, J.R. Andrews, V. Vella, A.P. Moll, M. Scott, D. Weissman, C. Marra, U.G. Lalloo, G.H. Friedland Tugela Ferry Care and Research (TF CARES) Collaboration HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality Am J Respir Crit Care Med 181 2010 80 86
3. World Health Organization Anti-tuberculosis drug resistance in the world. Fourth global report 2008 World Health Organization Geneva, Switzerland Report no: WHO/HTM/TB/2008.394
4. M. Gengenbacher, and S.H. Kaufmann Mycobacterium tuberculosis: success through dormancy FEMS Microbiol Rev 2012 1 19
5. G.A. Colditz, C.S. Berkey, F. Mosteller, T.F. Brewer, M.E. Wilson, E. Burdick, and H.V. Fineberg The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature Pediatrics 96 1995 29 35
6. P.E. Fine Variation in protection by BCG: implications of and for heterologous immunity Lancet 346 1995 1339 1345
7. S.H. Kaufmann, G. Hussey, and P.-H. Lambert New vaccines for tuberculosis Lancet 375 2010 2110 2119
8. Y.A. Skeiky, M.J. Lodes, J.A. Guderian, R. Mohamath, T. Bement, M.R. Alderson, and S.G. Reed Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis Infect Immun 67 1999 3998 4007
9. Y.A. Skeiky, M.R. Alderson, P.J. Ovendale, J.A. Guderian, L. Brandt, D.C. Dillon, A. Campos-Neto, Y. Lobet, W. Dalemans, I.M. Orme, and S.G. Reed Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein J Immunol 172 2004 7618 7628
10. D.C. Dillon, M.R. Alderson, C.H. Day, D.M. Lewinsohn, R. Coler, T. Bement, A. Campos-Neto, Y.A. Skeiky, I.M. Orme, A. Roberts, S. Steen, W. Dalemans, R. Badaro, and S.G. Reed Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family Infect Immun 67 1999 2941 2950
11. N. Garçon, P. Chomez, and M. Van Mechelen GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives Expert Rev Vaccines 6 2007 723 739
12. N. Garçon, and M. Van Mechelen Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems Expert Rev Vaccines 10 2011 471 486
13. S. Reed, and Y. Lobet Tuberculosis vaccine development; from mouse to man Microbes Infect 7 2005 922 931
14. L. Brandt, Y.A. Skeiky, M.R. Alderson, Y. Lobet, W. Dalemans, O.C. Turner, R.J. Basaraba, A.A. Izzo, T.M. Lasco, P.L. Chapman, S.G. Reed, and I.M. Orme The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs Infect Immun 72 2004 6622 6632
15. L. Tsenova, R. Harbacheuski, A.L. Moreira, E. Ellison, W. Dalemans, M.R. Alderson, B. Mathema, S.G. Reed, Y.A. Skeiky, and G. Kaplan Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis Infect Immun 74 2006 2392 2401
16. S.G. Reed, R.N. Coler, W. Dalemans, E.V. Tan, E.C. DeLa Cruz, R.J. Basaraba, I.M. Orme, Y.A. Skeiky, M.R. Alderson, K.D. Cowgill, J.P. Prieels, R.M. Abalos, M.C. Dubois, J. Cohen, P. Mettens, and Y. Lobet Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys Proc Natl Acad Sci U S A 106 2009 2301 2306
17. A candidate tuberculosis vaccine in purified protein derivative-negative adults Clin Vaccine Immunol 17 2010 1763 1771
18. K. Von Eschen, R. Morrison, M. Braun, O. Ofori-Anyinam, E. De Kock, P. Pavithran, M. Koutsoukos, P. Moris, D. Cain, M.C. Dubois, J. Cohen, and W.R. Ballou The candidate tuberculosis vaccine Mtb72F/AS02A: tolerability and immunogenicity in humans Hum Vaccin 5 2009 475 482
19. A induces strong cross-reactive and polyfunctional CD4 T-cell responses J Clin Immunol 31 2011 443 454
20. K.A. Wilkinson, and R.J. Wilkinson Polyfunctional T cells in human tuberculosis Eur J Immunol 40 2010 2139 2142
21. ® against Mycobacterium tuberculosis is highly dependent on the antigen dose PLoS One 4 2009 e5930
22. + T cell responses directed to dominant and subdominant epitopes in ESAT-6 from Mycobacterium tuberculosis J Immunol 183 2009 2659 2668
23. E.K. Forbes, C. Sander, E. Ronan, H. McShane, A.V. Hill, P.C. Beverley, and E.Z. Tchilian The presence of multifunctional, high-cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice J Immunol 181 2008 4955 4964
24. T. Lindenstrøm, E.M. Agger, K.S. Korsholm, P.A. Darrah, C. Aagaard, R.A. Seder, I. Rosenkrands, and P. Andersen Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells J Immunol 182 2009 8047 8055
25. C. Aagaard, T. Hoang, J. Dietrich, P.J. Cardona, A. Izzo, G. Dolganov, G.K. Schoolnik, J.P. Cassidy, R. Billeskov, and P. Andersen A multistage tuberculosis vaccine that confers efficient protection before and after exposure Nat Med 17 2011 189 194
26. + T cell responses discriminate between latent infection and active disease Nat Med 17 2011 372 376
27. + T cell-dependent activation of NK cells following vaccination J Immunol 185 2010 2808 2818
28. J.H. Evans, A. Horowitz, M. Mehrabi, E.L. Wise, J.E. Pease, E.M. Riley, and D.M. Davis A distinct subset of human NK cells expressing HLA-DR expand in response to IL-2 and can aid immune responses to BCG Eur J Immunol 41 2011 1924 1933
29. P. Vandepapelière, Y. Horsmans, P. Moris, M. Van Mechelen, M. Janssens, M. Koutsoukos, P. Van Belle, F. Clement, E. Hanon, M. Wettendorff, N. Garçon, and G. Leroux-Roels Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers Vaccine 26 2008 1375 1386
30. + T cells induce innate responses independently of pathogen Nat Med 16 2010 558 564
31. E.M. Leyten, C. Prins, A.W. Bossink, S. Thijsen, T.H. Ottenhoff, J.T. van Dissel, and S.M. Arend Effect of tuberculin skin testing on a Mycobacterium tuberculosis-specific interferon-γ assay Eur Respir J 29 2007 1212 1216
32. H. Mahomed, E.J. Hughes, T. Hawkridge, D. Minnies, E. Simon, F. Little, W.A. Hanekom, L. Geiter, and G.D. Hussey Comparison of Mantoux skin test with three generations of a whole blood IFN-γ assay for tuberculosis infection Int J Tuberc Lung Dis 10 2006 310 316
33. M.X. Rangaka, K.A. Wilkinson, R. Seldon, G. Van Cutsem, G.A. Meintjes, C. Morroni, P. Mouton, L. Diwakar, T.G. Connell, G. Maartens, and R.J. Wilkinson Effect of HIV-1 infection on T-cell-based and skin test detection of tuberculosis infection Am J Respir Crit Care Med 175 2007 514 520
34. J.S. Friedland, J.C. Hartley, C.G.C. Hartley, R.J. Shattock, and G.E. Griffin Inhibition of ex vivo proinflammatory cytokine secretion in fatal Mycobacterium tuberculosis infection Clin Exp Immunol 100 1995 233 238
35. F. Poveda, J. Camacho, F. Arnalich, R. Codoceo, A. del Arco, and P. Martínez-Hernández Circulating cytokine concentrations in tuberculosis and other chronic bacterial infections Infection 27 1999 272 274
36. V.F. Quesniaux, M. Jacobs, N. Allie, S. Grivennikov, S.A. Nedospasov, I. Garcia, M.L. Olleros, Y. Shebzukhov, D. Kuprash, V. Vasseur, S. Rose, N. Court, R. Vacher, and B. Ryffel TNF in host resistance to tuberculosis infection Curr Dir Autoimmun 11 2010 157 179
37. G.A.W. Rook Th2 cytokines in susceptibility to tuberculosis Curr Mol Med 7 2007 327 337
38. J.I. Cohen, P. Hohman, R. Fulton, S.P. Turk, J. Qin, K. Thatcher, and R.L. Hornung Kinetics of serum cytokines after primary or repeat vaccination with the smallpox vaccine J Infect Dis 201 2010 1183 1191